Bavarian's sales of travel vaccines impress major bank
Major Nordic bank Nordea raises its price target on Bavarian Nordic to DKK 350 from DKK 340. The bank also reiterates its ’buy’ recommendation following the vaccine company’s third-quarter results, which showed strong growth in sales of travel vaccines.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic bats its eye at travel vaccines on RSV flop
For subscribers